Since Ipilimumab as the first immune checkpoint inhibitor (ICI) was approved by the Food and Drug Administration (FDA) for the treatment of melanoma patients in 2011 [8], ICIs have been investigated in a variety of cancers to the extent that now many anti-PD-1, anti-programmed-death ligand 1 (PD-L1), and anti-CTLA-4 medications like Nivolumab, Pembrolizumab, and Atezolizumab achieved FDA approval for non-small-cell lung cancer (NSCLC) [9–11], renal cell carcinoma [12, 13], head and neck squamous cell carcinoma [14, 15], and urothelial cancer [16]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.